Business Context and Reporting Period
Company: Pfizer Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 3, 2005
Business Overview: Pfizer is a global research-based pharmaceutical company. The quarter was significantly impacted by the FDA-mandated suspension of sales for the COX-2 inhibitor Bextra, the repatriation of foreign earnings under the American Jobs Creation Act of 2004, and ongoing patent expirations for major products like Neurontin and Diflucan.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2005 | Q1 2004 |
|---|---|---|
| Revenues | $13,091 | $12,487 |
| Net Income | $301 | $2,331 |
| Diluted EPS | $0.04 | $0.30 |
| Operating Cash Flow | $3,174 | $1,583 |
| Effective Tax Rate | 90.6% | 25.8% |
| Total Debt | $19,831 | $18,545 |
| Cash & Short-term Investments | $21,971 | $19,893 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5% year-over-year, driven by a weaker U.S. dollar (+3.2% impact), strong performance of Lipitor and Zithromax, and three additional business days in the quarter. This growth was offset by declines in Celebrex, Bextra, and products facing generic competition (Neurontin, Diflucan, Accupril).
- Profitability Collapse: Net income plummeted 87% to $301 million. This was primarily due to two massive non-recurring charges:
- Bextra Suspension: A pre-tax charge of $1,213 million ($766 million net of tax) related to asset impairments, inventory write-offs, and customer returns following the FDA withdrawal of Bextra.
- Tax Repatriation: A one-time income tax charge of $2,189 million related to the repatriation of $28.3 billion in foreign earnings under the American Jobs Creation Act of 2004.
- Adjusted Income: Management reported "Adjusted Income" of $4.0 billion, up 1% from $3.976 billion in Q1 2004, excluding the significant items noted above, purchase accounting adjustments, and merger-related costs.
- Segment Performance: Human Health revenues grew 4% to $11.4 billion. Consumer Healthcare grew 17% and Animal Health grew 16%.
Guidance, Outlook, and Risks
- 2005 Outlook:
- Full-Year Revenue: Expected to be substantially unchanged from 2004, as growth from new products offsets patent expirations and COX-2 impacts.
- Adjusted Income: Projected at approximately $14.7 billion.
- Reported Net Income: Projected at approximately $7.7 billion.
- EPS: Adjusted diluted EPS expected at $1.98; Reported diluted EPS expected at $1.04.
- Adapting to Scale (AtS) Initiative: Launched a company-wide initiative targeting $4 billion in annual cost savings by 2008. Total pre-tax expenditures for this multi-year effort are estimated at $5 to $6 billion, with costs beginning in Q3 2005.
- Key Risks:
- Regulatory Actions: Ongoing FDA and EMEA reviews of COX-2 drugs (Celebrex) and potential labeling changes.
- Patent Expirations: Continued loss of exclusivity for major products (Zithromax in 2005, Zoloft in 2006, Norvasc/Zyrtec in 2007).
- Legal Proceedings: Ongoing litigation regarding product liability, patent challenges, and foreign sales activities.
Investor Verification Checklist
- Bextra Impact: Verify the extent of the $1.2 billion charge and the status of the FDA review for Celebrex, which remains on the market but with new warnings.
- Tax Repatriation: Confirm the potential reduction of the $2.2 billion tax charge by up to $850 million pending technical corrections legislation.
- Patent Cliff: Assess the specific revenue impact of Zithromax patent expiration in late 2005 and the subsequent loss of exclusivity for Zoloft and Norvasc.
- Adjusted Income Reconciliation: Review the reconciliation between GAAP Net Income and Adjusted Income to understand the magnitude of non-recurring charges excluded from management's performance metrics.
- Share Repurchase Program: Monitor the execution of the $5 billion share repurchase program, with $2.4 billion targeted for completion in Q2 2005.